| Index | — | P/E | 31.29 | EPS (ttm) | 0.34 | Insider Own | 13.08% | Shs Outstand | 45.88M | Perf Week | 7.37% |
| Market Cap | 488.21M | Forward P/E | 15.39 | EPS next Y | 0.69 | Insider Trans | 0.08% | Shs Float | 45.23M | Perf Month | 9.02% |
| Enterprise Value | 629.21M | PEG | 0.50 | EPS next Q | — | Short Float | 10.87% | Perf Quarter | -0.65% | ||
| Income | 15.00M | P/S | 0.94 | EPS this Y | -35.59% | Short Ratio | 7.93 | Perf Half Y | -24.38% | ||
| Sales | 517.00M | P/B | 1.72 | EPS next Y | 45.34% | ROA | 2.62% | Short Interest | 4.92M | Perf YTD | -33.62% |
| Book/sh | 6.19 | P/C | 23.25 | EPS next 5Y | 37.91% | ROE | 5.73% | 52W High | 20.36 -47.74% | Perf Year | -33.95% |
| Cash/sh | 0.46 | P/FCF | 23.25 | EPS past 3/5Y | 17.42% — | ROIC | 4.38% | 52W Low | 9.13 16.54% | Perf 3Y | -53.37% |
| Dividend Est. | 0.04 (0.38%) | EV/EBITDA | 11.44 | Sales past 3/5Y | 2.46% 1.59% | Gross Margin | 17.67% | Volatility | 4.56% 4.15% | Perf 5Y | -62.31% |
| Dividend TTM | 0.04 (0.38%) | EV/Sales | 1.22 | EPS Y/Y TTM | -49.76% | Oper. Margin | 7.57% | ATR (14) | 0.45 | Perf 10Y | -89.94% |
| Dividend Ex-Date | Nov 09, 2026 | Quick Ratio | 1.60 | Sales Y/Y TTM | -0.19% | Profit Margin | 3.01% | RSI (14) | 54.87 | Recom | 2.68 |
| Dividend Gr. 3/5Y | 0.00% -32.24% | Current Ratio | 2.19 | EPS Q/Q | -27.27% | SMA20 | 5.02% | Beta | 1.18 | Target Price | 21.00 |
| Payout | 11.80% | Debt/Eq | 0.57 | Sales Q/Q | -2.22% | SMA50 | -3.18% | Rel Volume | 1.48 | Prev Close | 10.40 |
| Employees | 3,300 | LT Debt/Eq | 0.53 | Earnings | Feb 03 | SMA200 | -23.27% | Avg Volume | 596.47K | Price | 10.64 |
| IPO Date | Sep 21, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.11% 0.16% | Net Debt/EBITDA | 2.56 | Volume | 880,172 | Change | 2.31% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Reiterated | Johnson Rice | $21 | |
| Mar-12-25 | Upgrade | Citigroup | Sell → Neutral | |
| Jul-15-24 | Reiterated | Piper Sandler | Neutral | $18 → $17 |
| Apr-18-23 | Downgrade | B of A Securities | Neutral → Underperform | |
| Feb-07-23 | Reiterated | Citigroup | Neutral | $26 |
| Jan-09-23 | Upgrade | B of A Securities | Underperform → Neutral | |
| Oct-07-22 | Upgrade | Citigroup | Sell → Neutral | |
| Sep-26-22 | Downgrade | Morgan Stanley | Equal Weight → Underweight | |
| May-02-22 | Reiterated | Morgan Stanley | Equal Weight | $32 |
| Apr-18-22 | Downgrade | Piper Sandler | Neutral → Underweight |
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly segmented into Reservoir Description and Production Enhancement. The Reservoir Description division meticulously analyzes petroleum reservoir rock, fluid, and gas samples. This detailed scientific examination aims to boost the yield and enhance the recovery of oil and gas from clients' reservoirs. Offerings in this segment encompass comprehensive laboratory analysis and on-site field evaluations to determine the properties of crude oil and refined products, alongside performing proprietary and collaborative industry research studies. Conversely, the Production Enhancement segment furnishes an array of services and products vital for well completions, perforations, stimulation processes, and general production activities. This includes providing integrated diagnostic tools designed to assess the efficacy of well completions and to devise strategies for more effective enhanced oil recovery initiatives. Core Laboratories markets and sells its solutions through diverse channels, including direct sales representatives, educational seminars, industry trade exhibitions, print advertising, and a network of distributors. Established in 1936, the company boasts a significant international presence, conducting operations in approximately 50 countries, with its corporate headquarters situated in Amstelveen, the Netherlands.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 517 | 527 | 524 | 510 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 425 | 432 | 435 | 416 | — | — | — | — | — | |
| Gross Profit | 91 | 94 | 88 | 94 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 46 | 44 | 39 | 39 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 6 | 0 | -9 | 0 | — | — | — | — | — | |
| Operating Income | 39 | 50 | 59 | 55 | — | — | — | — | — | |
| Interest Expense | 12 | 11 | 12 | 13 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 6 | 0 | 0 | — | — | — | — | — | |
| Net Income Before Taxes | 27 | 46 | 46 | 41 | — | — | — | — | — | |
| Income Taxes | 13 | 16 | 14 | 4 | — | — | — | — | — | |
| Consolidated Net Income | 15 | 30 | 31 | 37 | — | — | — | — | — | |
| Net Income From Continuing Operations | 15 | 30 | 32 | 37 | — | — | — | — | — | |
| Net Income | 15 | 30 | 31 | 37 | — | — | — | — | — | |
| EPS (Recurring) | 0.34 | 0.68 | 0.67 | 0.79 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.34 | 0.68 | 0.67 | 0.79 | — | — | — | — | — | |
| EPS (Diluted) | 0.34 | 0.68 | 0.66 | 0.77 | — | — | — | — | — | |
| EBITDA | 55 | 71 | 74 | 70 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 31.29 | 23.57 | 26.23 | 22.94 | — | — | — | — | — | |
| Price To Sales Ratio | 0.97 | 1.43 | 1.55 | 1.63 | — | — | — | — | — | |
| Gross Margin | 17.60 | 17.84 | 16.79 | 18.43 | — | — | — | — | — | |
| Operating Margin | 7.54 | 9.49 | 11.26 | 10.78 | — | — | — | — | — | |
| Net Margin | 2.90 | 5.69 | 5.92 | 7.25 | — | — | — | — | — | |
| Shares Outstanding | 47 | 47 | 47 | 47 | — | — | — | — | — | |
| Market Capitalization | 500 | 753 | 814 | 830 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Teo Sow Hang | CAO & Treasurer | Oct 01 '26 | Option Exercise | 0.00 | 250 | 0 | 8,917 | Oct 05 |
| Tattoli Mark Damian | SVP, Gen Counsel & Secretary | Oct 01 '26 | Option Exercise | 0.00 | 700 | 0 | 28,365 | Oct 05 |
| Teo Sow Hang | CAO & Treasurer | Aug 01 '26 | Option Exercise | 0.00 | 440 | 0 | 8,775 | Aug 04 |
| Tattoli Mark Damian | SVP, Gen Counsel & Secretary | Aug 01 '26 | Option Exercise | 0.00 | 250 | 0 | 27,764 | Aug 04 |
| Bruno Lawrence | Chairman and CEO | Jul 31 '26 | Buy | 10.78 | 5,000 | 53,900 | 262,438 | Aug 04 |
| Tattoli Mark Damian | SVP, Gen Counsel & Secretary | May 01 '26 | Option Exercise | 0.00 | 250 | 0 | 27,611 | May 04 |
| Murray Katherine | Director | Apr 01 '26 | Option Exercise | 0.00 | 8,069 | 0 | 29,290 | Apr 08 |
| ANASTASIO CURT | Director | Apr 01 '26 | Option Exercise | 0.00 | 8,069 | 0 | 23,805 | Apr 07 |
| Klingensmith Harvey Robert | Director | Apr 01 '26 | Option Exercise | 0.00 | 8,069 | 0 | 50,031 | Apr 07 |
| Temeng Kwaku | Director | Apr 01 '26 | Option Exercise | 0.00 | 8,069 | 0 | 33,597 | Apr 07 |
| MARTINOVICH ROBERT F | Director | Apr 01 '26 | Option Exercise | 0.00 | 8,069 | 0 | 8,069 | Apr 07 |
| Carnes Martha Z. | Director | Apr 01 '26 | Option Exercise | 0.00 | 8,069 | 0 | 54,397 | Apr 07 |
| Tattoli Mark Damian | SVP, Gen Counsel & Secretary | Dec 31 '25 | Option Exercise | 0.00 | 24,952 | 0 | 41,671 | Jan 05 |
| Gresham Gwendolyn | SVP | Dec 31 '25 | Option Exercise | 0.00 | 24,952 | 0 | 52,527 | Jan 05 |
| Hill Christopher Scott | SVP & CFO | Dec 31 '25 | Option Exercise | 0.00 | 61,417 | 0 | 142,354 | Jan 05 |